TP53 and glioblastoma: In this study, we found that, compared with p53 wild-type GBM patients who received TMZ treatment, the mOS and mPFS of p53 mutant GBM patients were shortened to some extent, although the differences were not all statistically significant (mOS of control group: 15.95 months vs.16.80 months, P = 0.949; mOS of extended group: 29.00 months vs.46.00 months, P = 0.309; mPFS of control group: 9.30 months vs.11.50 months, P = 0.940; mPFS of extended group: 13.15 months vs.15.50 months, P = 0.039).